News
ALXO
2.040
+2.51%
0.050
Weekly Report: what happened at ALXO last week (0810-0814)?
Weekly Report · 5d ago
H.C. Wainwright Reaffirms Their Buy Rating on ALX Oncology Holdings (ALXO)
TipRanks · 08/10 13:17
Weekly Report: what happened at ALXO last week (0803-0807)?
Weekly Report · 08/10 09:48
Analysts Have Conflicting Sentiments on These Healthcare Companies: Astrana Health (ASTH) and ALX Oncology Holdings (ALXO)
TipRanks · 08/07 01:00
ALX Oncology Holdings Q2 Adj. EPS $(0.11) Beats $(0.14) Estimate
Benzinga · 08/06 12:39
ALX Oncology GAAP EPS of -$0.13
Seeking Alpha · 08/06 12:14
*ALX Oncology 2Q Loss/Shr 13c >ALXO
Dow Jones · 08/06 12:00
Press Release: ALX Oncology Reports Second -2-
Dow Jones · 08/06 12:00
Press Release: ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Dow Jones · 08/06 12:00
*ALX Oncology 2Q Loss $18M >ALXO
Dow Jones · 08/06 12:00
Weekly Report: what happened at ALXO last week (0727-0731)?
Weekly Report · 08/03 09:48
Weekly Report: what happened at ALXO last week (0720-0724)?
Weekly Report · 07/27 09:51
Weekly Report: what happened at ALXO last week (0713-0717)?
Weekly Report · 07/20 09:48
Weekly Report: what happened at ALXO last week (0706-0710)?
Weekly Report · 07/13 09:50
BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?
NASDAQ · 07/09 17:34
Weekly Report: what happened at ALXO last week (0629-0703)?
Weekly Report · 07/06 09:52
ALX Oncology Appoints New Chairman Amid Leadership Changes
TipRanks · 06/30 20:39
ALX Oncology Appoints Scott Garland Chairman, Effective Immediately, Succeeding Corey Goodman
Benzinga · 06/30 12:12
ALX Oncology chairman Corey Goodman steps down, Scott Garland succeeds
TipRanks · 06/30 12:05
Weekly Report: what happened at ALXO last week (0622-0626)?
Weekly Report · 06/29 09:49
More
Webull provides a variety of real-time ALXO stock news. You can receive the latest news about Alx Oncology Holdings Inc through multiple platforms. This information may help you make smarter investment decisions.
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company advancing a pipeline of therapies designed to treat cancer and extend patients’ lives. The Company's lead product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, antibody drug conjugate (ADCs), and PD-1/PD-L1 immune checkpoint inhibitors. Evorpacept is being evaluated across multiple ongoing clinical trials in a range of cancer indications. Its second product candidate is ALX2004, an epidermal growth factor receptor (EGFR)-targeted ADC. ALX2004 comprises an affinity-tuned EGFR antibody backbone engineered for optimal activity as an ADC, a proprietary topoisomerase I inhibitor payload with enhanced bystander effect, and a linker with enhanced stability.